stoxline Quote Chart Rank Option Currency Glossary
  
GRI Bio, Inc. (GRI)
1.36  0.02 (1.49%)    06-17 16:00
Open: 1.37
High: 1.38
Volume: 48,273
  
Pre. Close: 1.34
Low: 1.33
Market Cap: 3(M)
Technical analysis
2025-06-17 4:44:07 PM
Short term     
Mid term     
Targets 6-month :  1.67 1-year :  1.89
Resists First :  1.43 Second :  1.62
Pivot price 1.35
Supports First :  1.12 Second :  0.94
MAs MA(5) :  1.34 MA(20) :  1.34
MA(100) :  4.41 MA(250) :  10.62
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  47.3 D(3) :  53.5
RSI RSI(14): 42.7
52-week High :  59.33 Low :  1.1
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GRI ] has closed below upper band by 47.8%. Bollinger Bands are 93.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 40 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.38 - 1.39 1.39 - 1.39
Low: 1.32 - 1.32 1.32 - 1.33
Close: 1.35 - 1.36 1.36 - 1.37
Company Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Headline News

Wed, 11 Jun 2025
# H.C. Wainwright REITERATES Buy rating on GRI Bio stock - Investing.com

Fri, 23 May 2025
GRI Bio expands at-the-market offering capacity - Investing.com

Thu, 22 May 2025
GRI Bio Reports Positive Preclinical Data For GRI-0621 - Nasdaq

Thu, 22 May 2025
GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire

Wed, 21 May 2025
GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire

Wed, 21 May 2025
GRI Bio CEO Reveals Next Steps in NKT Cell Therapy Development at Virtual Investor Series - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 2 (M)
Shares Float 2 (M)
Held by Insiders 0 (%)
Held by Institutions 0.2 (%)
Shares Short 65 (K)
Shares Short P.Month 252 (K)
Stock Financials
EPS 40.06
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.28
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -136.1 %
Return on Equity (ttm) -468 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio 0.03
PEG Ratio 0
Price to Book value 0.59
Price to Sales 0
Price to Cash Flow -0.4
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android